| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT05053659 Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
date change Primary completion pushed: 2026-06 -> 2026-11 |
| 2026-06-06 | NCT05053659 Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
date change Completion pushed: 2026-06 -> 2026-11 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in… | Relapsed Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory… | B-cell Non Hodgkin Lymphoma | Recruiting |
| Phase 2 | |||
| NCT06919939 | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large… | Large B-cell Lymphoma | Recruiting |
| NCT04998669 | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or… | Follicular Lymphoma | Recruiting |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Recurrent B-Cell Non-Hodgkin Lymphoma | Recruiting |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory… | Recurrent Diffuse Large B-Cell Lymphoma | Recruiting |
| NCT05464719 | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With… | Large B-cell Lymphoma | Recruiting |
| NCT06788964 | Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T… | Relapsed or Refractory Large B-cell Lymphoma | Recruiting |
| NCT05190705 | Loncastuximab Tesirine in WM | Waldenstrom Macroglobulinemia | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07573436 | Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With… | Post-transplant Lymphoproliferative Disorder | Not Yet Recruiting |
| NCT05658562 | A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT04970901 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in… | B-Cell Non-Hodgkin Lymphoma | Recruiting |
| NCT05053659 | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Active, Not Recruiting |